Skip to content

Digital Phenotyping for Psychosocial Screening in Adolescents and Young Adults With Cancer

Using Digital Phenotyping to Optimize Psychosocial Risk Screening and Personalized Care: a Pilot Study in Adolescents and Young Adults With Cancer

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07220343
Enrollment
25
Registered
2025-10-23
Start date
2025-01-29
Completion date
2026-12-31
Last updated
2025-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescents, Cancer

Keywords

Smartphone, Cancer

Brief summary

The overall goal of the proposed study is to use digital phenotyping to identify and triage at-risk patients and accelerate access to critical mental health services.

Interventions

DEVICEDevice

Participants will wear a wrist-based wearable device for 10 days to passively track physiological data (heart rate, steps, sleep, etc.).

BEHAVIORALEcological Momentary Assessment (EMA) via My Personal Health Dashboard (MyPHD) Smartphone App

Participants will respond to ecological momentary assessments (EMA) via smartphone to actively report on sleep, mood, stress, and eating habits across a 10-day period.

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

* 10-25 years old * Recent cancer diagnosis (\>2 and \<18 months since diagnosis) * Willing to carry smartphone on their person for duration of study participation * Willing to wear smartwatch for duration of study participation

Exclusion criteria

* Significant physical or mental disability that prevents completion of study activities * Lack of proficiency in English or Spanish

Design outcomes

Primary

MeasureTime frameDescription
Change in Depressive Symptoms (Beck Depression Inventory - BDI)Baseline, Day 10, 2 monthsThe Beck Depression Inventory-II (BDI-II; range 0-63) will be used to measure changes in depressive symptoms among adolescents and young adults over time. Higher scores indicate greater depressive symptom severity.

Secondary

MeasureTime frameDescription
Adherence to EMA PromptsBaseline to 2 monthsMean percentage of EMA prompts completed by participants using the MyPHD mobile app during the 2-month study period. Completion will be assessed via EMA system analytics.
Wearable Device Return and Use RateBaseline to 2 monthsPercentage of participants who return and use the wearable device as instructed during the study period. Device use will be tracked through backend device usage logs.
Change in Anxiety Symptoms (Beck Anxiety Inventory - BAI)Baseline, Day 10, 2 monthsMeasures changes in self-reported anxiety symptoms across the study period.
Participant Retention Rate (MyPHD App and Wearable Device)Baseline to 2 monthsPercentage of participants who remain active in the study through the 2-month follow-up period using the MyPHD app and wearable device.
Change in PTSD Symptoms (PCL-5)BaselinePTSD symptoms are measured using the PTSD Checklist for DSM-5 (PCL-5) for general population participants.
Change in Sleep Quality (Pittsburgh Sleep Quality Index - PSQI)Baseline, Day 10Assesses subjective sleep quality and patterns.
Change in PTSD Symptoms (CROPS)BaselinePTSD symptoms are measured using the Child Report of Post-traumatic Symptoms (CROPS) for child participants.

Countries

United States

Contacts

Primary ContactOlivia Borge
oborge@stanford.edu(650) 723-9392

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026